Mast Therapeutics, Inc. (MSTX)

[BooDog]

Watching a small bio move forward can be agonizing sometimes. And seeing how compensation is awarded seemingly for the smallest event. Events add up and sooner or later we hope to see the events lead into the drug getting where it needs to get, against the odds ~ approval.

Compensation is however, hard to swallow when these events seem immaterial. We are seeing progress.

This didn't really paste correctly, starts on p21 and goes on from there. Note the exercise prices as well. Weighted at the $ ranging from .47 to 2.75. I try to at least glance at these but not always. Milestones are to be compensated imo, just a matter of how greedy some companies get.

Corporate Objective

Weight

Achievement

Product Development – Vepoloxamer

80%



Enrollment in the EPIC study



Exceeded objective

Enrollment in Phase 2 ALI study



Partially met objective

Progress with Phase 2 development in heart failure



Partially met objectives

Progress with CMC-related(1) initiatives



Partially met objectives

Conduct of nonclinical stroke study



Met objective

Conduct of nonclinical trauma study



Did not meet objective

Progress with intellectual property-related initiatives



Exceeded objective

Product Development – AIR001

10%



Data generation from Phase 2 PAH(2) study



Met objective

Progress with institution-sponsored Phase 2a studies in HFpEF(3)



Partially met objectives

Cash Management

10%



Year-end cash(4) consistent with forecast



Exceeded objective




(1)
“CMC” refers to chemistry, manufacturing and control.


(2)
“PAH” refers to pulmonary arterial hypertension.


(3)
“HFpEF” refers to heart failure with preserved ejection fraction.


(4)
“Cash” refers to cash, cash equivalents and investment securities.


http://www.sec.gov/Archives/edgar/data/1160308/000156459015003000/mstx-def14a_20150611.htm